Atrial Fibrillation

Atrial Fibrillation

Andexanet alfa is a recombinant factor Xa molecule that binds to and sequesters factor Xa inhibitors in the blood, making them unavailable to bind to native factor Xa.

In new-onset atrial fibrillation there is good evidence for obtaining a troponin T level. High levels are associated with highest rates of stroke, embolism, and cardiac mortality.

Dabigatran was shown in post-hoc analysis of the RE-LY trial to be associated with an increased risk of MI compared with warfarin.

Rivaroxaban when used to treat patients with atrial fibrillation who have had a previous MI is associated with higher risk for adverse events.

Whether to prescribe an antiplatelet or antithrombotic agent for a patient who has AF but is otherwise healthy can be a difficult decision.

Cardioversion for paroxysmal atrial fibrillation must include pre- and post-procedure anticoagulation to avoid thromboembolic risk.

Only one agent can be used for anticoagulation in individuals with mechanical valves.


Subscribe to

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

Please Wait 20 seconds or click here to close